StemCells (STEM) Merger Deal with Microbot Medical; SITO Mobile (SITO) Posts Strong Revenue Rise

Shares of StemCells Inc. (Nasdaq:STEM) climbed more than 50% in after-hours trading Monday as the biopharmaceutical company disclosed in a regulatory filing ( FORM 8-K ) with the U.S. Securities and Exchange Commission (SEC) an agreement and plan of merger and reorganization with Israeli-based medical device company Microbot Medical Ltd.

STEM stock finished the regular session in positive territory by 0.59% (or +$0.002) at $0.372, with a total volume of 208,722 shares traded

StemCells, which engages in the research, development, and commercialization of cell-based therapeutics and related technologies, has 11.70M Shares Outstanding Market Capitalization (intraday) of $4.35M and STEM stock 52-week range is from $0.33 to $7.56 per share



SITO Mobile Ltd. (Nasdaq:SITO) shares surged over 10% in the extended session Monday after the company delivered strong revenue growth in its quarterly financial results

For the second quarter 2016, SITO Mobile posted revenue of $9.88 million, a 168% increase year over year, and net income of $0.73 million, or $0.04 per share, compared to net loss of ($1.04) million, or ($0.07) per share in the same quarter the prior year

SITO stock closed at $4.09, down $0.06 (or -1.45%) and 41,912 of its shares changed hands during the day

SITO Mobile, which operates as a mobile location-based advertising platform for businesses, advertisers and brands, has 17.36M Shares Outstanding Market Capitalization (intraday) of $71.00M and SITO stock one-year range is between $1.55 and $6.15 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at